Laser Therapy & Stem Cell Regeneration: What the Research Now Shows
How low-level laser therapy activates your bone marrow to release stem cells — and why this matters for healing, aging, and neurological disease.
By Oren Ziv | April 2026 | 7 min read
Most people think of laser therapy as something used for surface-level treatments. But peer-reviewed research tells a more compelling story: low-level laser therapy (LLLT / photobiomodulation) can reach deep into bone marrow and stimulate release of your body’s own stem cells into circulation.
This has significant implications for tissue repair, cardiovascular recovery, and — based on recent animal and human studies — neurodegenerative conditions like Alzheimer’s disease. This article reviews what the evidence actually supports.
1. How Laser Light Stimulates Stem Cells
The primary cellular target of photobiomodulation is cytochrome c oxidase — an enzyme in the mitochondrial respiratory chain. When red or near-infrared photons are absorbed, it triggers:
- Increased ATP production
- Upregulation of growth factors (VEGF and others)
- Reduction in inflammatory cytokines
- Enhanced cell proliferation and survival
- Activation of nitric oxide pathways
In practice, this causes mesenchymal stem cells (MSCs) in bone marrow to proliferate faster, differentiate more readily, and migrate into the bloodstream to home in on damaged tissues.
A 2016 systematic review by Fekrazad et al. covering 30 studies confirmed that doses of 0.7–4 J/cm² at wavelengths of 600–700 nm are most effective for MSC proliferation.
30+
peer-reviewed studies on LLLT and mesenchymal stem cells
68%
reduction in brain amyloid burden in laser-treated AD mice (Oron & Oron, 2016)
3.8×
increase in circulating CD34+ stem cells after one bone marrow laser session in humans (Oron et al., 2022)
2. Laser to the Bone Marrow: The Alzheimer's Research
Oron and Oron (2016) used a 5XFAD transgenic mouse model with significant amyloid burden by age 4 months.
Protocol
LLLT to the bone marrow every 10 days for 2 months, starting at 4 months (progressive disease stage). 808 nm Ga-Al-As diode, 10 mW/cm², 100 seconds per session (1 J/cm²).
Results
- Memory improved to near wild-type levels (Object Recognition Test: 68.7% vs 47.3% in untreated AD mice)
- Brain amyloid burden dropped 68% in the hippocampus
- MSCs showed a 35% increase in amyloid phagocytosis after laser treatment in vitro
- CD11b activation (monocyte marker) increased by 10%
Proposed mechanism: laser activates bone marrow monocyte-lineage cells, which migrate to the brain and physically clear amyloid plaques through phagocytosis.
Reference: Oron A, Oron U. Photomedicine and Laser Surgery. 2016;34(12):627–630. doi:10.1089/pho.2015.4072
3. First Human Data: CD34+ Cells and Macrophages
Oron et al. (2022) conducted a pilot study on 15 volunteers — the first published human data of this kind.
Protocol
808 nm Ga-Al-As diode applied noninvasively to both tibias. 100 sec per leg, 1 J/cm², 10 mW/cm² at bone marrow depth. Blood sampled at baseline, 2 hours, 24–48 hours, and 4 days post-treatment.
Results
- CD34+ stem cells rose from 7.8% to 29.5% of mononucleated cells — nearly fourfold — peaking at 2–4 days (p < 0.01)
- Elevation detectable at 2 hours — indicating rapid release from BM niches, not just new proliferation
- Macrophages rose from 7.8% to 52.1% (p < 0.01)
- Levels returned to baseline ~40 days later and could be re-elevated with a second treatment
Reference: Oron A et al. Photobiomodulation, Photomedicine, and Laser Surgery. 2022. doi:10.1089/photob.2021.0123
4. What PBM Does to Mesenchymal Stem Cells
Fekrazad et al. (2016) reviewed 30 studies on PBM effects on MSCs from bone marrow, adipose tissue, dental pulp, and periodontal ligament:
- Nearly all studies showed positive effects on cell proliferation
- Optimal parameters: 0.7–4 J/cm² at 600–700 nm
- Effects are dose-dependent — doses above 6 J/cm² can inhibit rather than stimulate
- LLLT applied to BM in vivo caused MSCs later isolated from that marrow to proliferate faster in vitro — a lasting effect on the stem cell population itself
Reference: Fekrazad R et al. Photomedicine and Laser Surgery. 2016;34(11):533–542. doi:10.1089/pho.2015.4029
5. Clinical Relevance and Safety
- No cell extraction required — stem cells mobilized endogenously
- No in vitro culture — no contamination risk
- No injection — avoids cell death from direct implantation
- Noninvasive — applied externally through skin to bone
Long-term safety studies in mice show no pathological changes in any organ after multiple PBMT sessions to bone marrow. In human clinical trials post-AMI, no adverse effects observed at 3-month follow-up.
Frequently Asked Questions
Photobiomodulation uses low-power red or near-infrared light to stimulate cellular processes without heating or cutting tissue. Surgical lasers operate at much higher power densities and ablate tissue. PBMT is non-thermal — it works through photochemical effects on mitochondria.
No. The laser is applied externally through the skin over the tibia. No needle, no injection, no anesthesia required. Most patients feel nothing or mild warmth.
Protocols vary. The Alzheimer’s mouse study used six sessions over two months. The human pilot study showed significant stem cell mobilization from a single session. Clinical protocols are individualized.
No. The research is promising but largely preclinical. Laser therapy should not substitute for evidence-based specialist care. It may play a complementary role as the evidence matures.
All three papers cited in this article are available via their DOI links in the text above. They are published in Photomedicine and Laser Surgery and Photobiomodulation, Photomedicine, and Laser Surgery — both peer-reviewed journals.
Interested in Laser Therapy?
Book a consultation and find out whether photobiomodulation therapy is appropriate for your situation.